Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
our similar early study and recent confirming experiments using the same reagents reported by Sheng et al. failed to reproduce the phenotype of the loss of dopaminergic neurons, although the mRNA of LRRK2 was molecularly disrupted
results demonstrate that zLRRK2 is an ortholog of hLRRK2 and that the deletion of WD40 domain (show DCAF12L2 Proteins) of zLRRK2 provides a disease model for PD
this study reveals that LRRK2 is a new positive regulator of Rip2 and promotes inflammatory cytokine induction through the Nod1/2-Rip2 pathway.
phosphoproteomic and interactome study in the Drosophila brain provides a systematic analyses of R1441C hLRRK2-induced pathobiological mechanisms in this model. We demonstrate for the first time that the R1441C mutation located within the LRRK2 GTPase (show RACGAP1 Proteins) domain induces the enhanced phosphorylation of SV proteins in the brain
Carriers of additional Mendelian gene variants have younger ages at onset (AAO). The effect of additional Mendelian variants in LRRK2 G2019S mutation carriers, of which ATP13A2 (show ATP13A2 Proteins) variation is particularly common, may account for some of the variation in penetrance
Overexpression of CHIP decreased intracellular protein (show CKAP2 Proteins) levels of both G2385R mutant and wild-type LRRK2, while short interfering RNA CHIP knockdown had the opposite effect
The LRRK2 R1441C mutation was found in a Chinese early-onset Parkinson Disease patient for the first time. Literature review found that the manifestations of LRRK2-R1441C carriers were indistinguishable from sporadic Parkinson Disease patients.
Genetic variability in DNM3 (show DNM3 Proteins) modifies age of onset for LRRK2 Gly2019Ser parkinsonism.
the C allele, GC and CC genotype of LRRK2 R1628P variants contribute to the susceptibility of Parkinson disease in Asian. [meta-analysis]
Four cases were heterozygous for the LRRK2 c.6055G > A mutation, giving an allele frequency of 1.4 % in Parkinson's disease
Our results suggest LRRK2 may be involved in a wide variety of cellular processes and the results from this screen provide an important genetic resource for further evaluation of LRRK2 function
DaT (show SLC6A3 Proteins)-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
LRRK2 kinase activity in microglia can contribute to neuroinflammation in Parkinson's disease via phosphorylating p53 (show TP53 Proteins) at T304 and T377 site
an altered sphingolipid composition in Lrrk2(-/-) mouse brains, is reported.
findings reveal a novel function of LRRK2 in regulating EPO (show EPO Proteins) expression and imply a potentially novel relationship between PD genes and hematopoiesis.
In the present study demonstrated that the up-regulation of HOTAIR and LRRK2 in the midbrain of PD mice induced by MPTP (show PTPN2 Proteins).
that mutant LRRK2 may impair synaptic vesicle dynamics via aberrant phosphorylation of N-ethylmaleimide sensitive fusion
14-3-3theta can regulate LRRK2 and reduce the toxicity of mutant LRRK2 through a reduction of kinase activity.
LRRK2 has a role in microglia activation and sustainment of neuroinflammation.
p21-activated kinase 6 (PAK6 (show PAK6 Proteins)) as a novel interactor of leucine-rich repeat kinase 2 (LRRK2), a kinase involved in Parkinson's disease
The data implicate gain of LRRK2 function in the pathogenesis of Parkinson disease
show that the LRRK2 sequence and expression patterns are conserved between pig and human
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8.
leucine-rich repeat serine/threonine-protein kinase 2
, leucine-rich repeat kinase 2
, leucine-rich repeat serine/threonine-protein kinase 2-like
, augmented in rheumatoid arthritis 17